

# EXHIBIT B

## CURRICULUM VITAE

ALAN I. FADEN, M.D.

Title: Professor of Neuroscience, Neurology and Pharmacology  
Senior Scientist, Georgetown Institute for Cognitive and  
Computational Sciences

Business Address: Georgetown University Medical Center  
Research Building, Room EP-04  
3970 Reservoir Road, N.W.  
Washington, D.C. 20007-2197  
voice: (202) 687-2870; fax: (202) 687-0617  
e-mail: fadena@giccs.georgetown.edu

Home Address: 3339 Tennyson Street, N.W.  
Washington, D.C. 20015  
(202) 244-4490

Birthdate & Place: 11 January 1945  
Philadelphia, Pennsylvania

Licensure: California, G23664, 1972-present  
Maryland, D19048, 1975-present  
District of Columbia, 19067, 1991-present

Board Certification: Diplomat National Board of Medical Examiners, 1972  
American Board of Psychiatry and Neurology  
(Neurology, 1977)

Military Service: Major, Medical Corps, United States Army  
11 August 1975 – 31 July 1980

### Education

1962-66 B.A., University of Pennsylvania  
Physics (Honors)  
1966-67 Graduate Studies, Indiana University  
History and Philosophy of Science  
1967-71 M.D., University of Chicago School of Medicine

### Clinical Training

1971-72 Intern in Medicine, Presbyterian-University of Pennsylvania  
Medical Center  
1972-74 Resident in Neurology, University of California, San Francisco  
1974-75 Chief Resident in Neurology, University of California,  
San Francisco

## PRINCIPAL POSITIONS HELD

- 1975 University of California, San Francisco; Instructor in Neurology  
 1975-80 Walter Reed Army Institute of Research, Department of Medical  
 Neurosciences, Washington, D.C.: Research Neurologist  
 1977-84 Uniformed Services University of the Health Sciences  
 Assistant Professor of Neurology (1977-78)  
 Associate Professor of Neurology (1978-81) and Medicine (1980-81)  
 Vice-Chairman and Director of Research, Department of Neurology (1980-82)  
 Professor of Neurology (1981-84) and Physiology (1983-84)  
 Chief, Neurobiology Research Unit (1982-84)  
 1984-91 University of California, San Francisco  
 Vice-Chairman, Department of Neurology (1984-90)  
 Chief, Neurology Service, Department of Veterans Affairs,  
 San Francisco, CA (1984-90)  
 Director, Center for Neural Injury (1984-91)  
 Professor of Neurology in Residence (1984-91)  
 1991- Georgetown University, Washington, D.C.  
 Associate Dean for Biomedical Sciences, Graduate School (1991-95)  
 Dean of Research and Graduate Education, Medical Center (1991-96)  
 Scientific Director, Medical Center (1991-96)  
 Professor of Neurology and Pharmacology, Medical School (1991- )  
 Director, Georgetown Institute for Cognitive and Computational  
 Sciences (1995-98)  
 Professor of Neuroscience (1999- )

## Ancillary Positions Held Concurrently

- 1976-77 Visiting Research Scholar, Center for Bioethics, Kennedy Institute,  
 Georgetown University  
 1990-91 Visiting Professor, Department of Chemistry and Biochemistry,  
 James Cook University, Townsville, Queensland, Australia

## Clinical Appointments

- 1976-80 Howard County General Hospital and Montgomery County General  
 Hospital: Emergency Room Physician  
 1976-84 Walter Reed Army Medical Center, Washington, DC: Director,  
 Neurology Consultation Service and Chief of Clinical Research (1978-80)  
 1980-84 National Naval Medical Center, Bethesda, MD: Director, Neurology  
 Consultation Service (1980-81)  
 1982-84 National Institutes of Health, Bethesda, MD: Consultant, Clinical  
 Neurosciences Branch, Institute for Aging; and Consultant, Clinical Center  
 1984-91 V.A. Medical Center, San Francisco, CA: Chief of Neurology (1984-90)  
 1984-91 University of California, Hospitals and Clinics, San Francisco  
 1991-95 National Naval Medical Center, Bethesda, MD  
 1991- Georgetown University Medical Center

## HONORS AND AWARDS

- 1962-66 Mayor's Scholarship, University of Pennsylvania (Honors in Physics)  
 1966-67 National Science Foundation Fellowship, Indiana University  
 1967-71 Scholarship, University of Chicago Medical School  
 1975 Newman Award, San Francisco Neurological Society  
 1979 Keynote Speaker, Infectious Disease Society of America  
 1980 Letter of Appreciation, Undersecretary of the Army

- 1980 Letter of Commendation, Director, Medical Research and Development Command, United States Army
- 1980 Prize-Winning Paper and Outstanding Achievement Award, United States Army Science Conference
- 1980 Outstanding Achievement Award for Research, United States Army Research and Development Command
- 1982 100 Top Young Leaders of Washington, *Washingtonian* Magazine
- 1984 Exceptional Service Medal, Uniformed Services University of the Health Sciences
- 1984 Keynote Address, Second International Symposium on the Spinal Cord
- 1984 Keynote Address, American Osteopathic Association
- 1986 Janssen Distinguished Lecturer, Society of Neurosurgical Anesthesia
- 1987 Paralyzed Veterans of America Distinguished Lecturer, University of Washington
- 1988-89 President, Neurotrauma Society
- 1989 Knight Foundation Visiting Professor, University of Miami, School of Medicine
- 1990-91 President, San Francisco Neurological Society
- 1996 Faculty Convocation Address, Georgetown University
- 2000 Knight Foundation Visiting Professor, University of Miami, School of Medicine
- 2001 Distinguished Service Award, University of Chicago

## OTHER PROFESSIONAL ACTIVITIES

### Memberships in Professional Organizations

- 1973- American Academy of Neurology (Fellow):  
Scientific Affairs Committee (1987-88), McHenry Award Committee (1988)
- 1977- Society for Neuroscience
- 1977- American Association for the Advancement of Science
- 1980-85 New York Academy of Sciences
- 1981- American Society for Clinical Investigation
- 1981- American Neurologic Association: Local Affairs Chairman (1987);  
Co-Chairman (1995)
- 1981- American College of Physicians (Fellow)
- 1982- American Physiological Society
- 1983-87 Shock Society
- 1983- American Society for Pharmacology and Experimental Therapeutics
- 1986-91 San Francisco Neurological Society: Scientific Program Committee (1987, 1988), Secretary-Treasurer (1988-89), Vice-President (1989-90), President (1990-91)
- 1986- Stroke Council, American Heart Association
- 1988- Neurotrauma Society: President (1988-89)
- 1989- Society of Neurological Spectroscopy: Council Member (1989-91)
- 1993- International Society for Cerebral Blood Flow and Metabolism
- 1995- Molecular Medicine Society (Fellow)
- 1996- American Society for Experimental Neurotherapeutics: Treasurer, Executive Committee, Scientific Program Committee, Publication Committee

### Public Service

- 1985-86 Marin Arts Guild, Advisory Board
- 1985-88 Lectures to American Paralysis Association Chapters,  
National Head Injury Foundation, UCSF Public Lecture Series
- 1994-95 Medical Advisory Board, St. Patrick's Episcopal School
- 1994- Board of Directors, Aish Hatorah

### Boards and Scientific Advisory Activities

1983-84 Spinal Cord Society, Scientific Advisor  
 1983-84 Henry G. Stifel III Spinal Cord Injury Foundation, Scientific Advisor  
 1984-85 American Paralysis Association, Scientific Advisory Board  
 1984-90 National Research Institute for Neural Injury;  
     Member, Board of Directors and Scientific Director  
 1988-94 Medicis Pharmaceutical Corporation: Member, Board of Directors  
 1991-94 National Biomedical Research Foundation; Member, Board of Directors  
 1991-94 Fidia-Georgetown Institute for the Neurosciences;  
     Member, Board of Directors  
 1992-95 International Scientific Council, The European Center for Clinical  
     Pharmacology  
 1992-96 Executive Committee, Lombardi Cancer Center, SPORE  
 1992-96 Internal Advisory Committee: Excitotoxins Program Project (GUMC)  
 1994-96 Steering Committee, Institute for Health Care Research and Policy  
     (GUMC)  
 1994-96 Steering Committee, Institute for Cardiovascular Sciences (GUMC)  
 1996- Advisory Board, Applied Neurology Institute, Purdue University  
 1999- External Scientific Advisory Board, Head Injury Center,  
     University of Pennsylvania  
 2000 Scientific Advisory Board, Institute for The Study of Aging

### Professional Organization Activities

1982 Co-Chairman, Satellite Symposium on CNS Trauma Society for Neuroscience  
 1981 *Ad Hoc* Study Section, National Institute of Neurological and Communicative  
     Disorders and Stroke  
 1983-91 Scientific Director, National Research Institute for Neural Injury  
 1983-91 Scientific Reviewer, Paralyzed Veterans of America  
 1981-84 Guest Scientist, Naval Medical Research Institute  
 1985 Scientific Advisory Panel Member, National Council for the Handicapped  
 1986 Co-Chair and Organizer, Satellite Symposium,  
     International Society of Hypertension  
 1987 Organizing Committee, Third International Symposium on the  
     Neurochemistry of Spinal Cord Injury  
 1987, 1988 Course Director, Neuropharmacology Course, American Academy of  
     Neurology  
 1988 Chair, Special Review Committee, National Institute of Neurological  
     Disorders and Stroke  
 1988 Organizing Committee, Sixth Annual Neurotrauma Symposium  
 1989 Conference Chairman, The Neurobiology of CNS Injury, FASEB Symposium  
 1989 Site Visit Team, *Ad Hoc* Study Section, National Institute of Neurological  
     Disorders and Stroke  
 1989 Scientific Briefing, Office of Technology Assessment, U.S. Congress  
 1990 Conference Co-Chairman, FASEB Symposium, CNS Trauma  
 1992, 1994 Workshop Chair, Winter Conference on Brain Research  
 1994 *Ad Hoc* Study Section, National Institute for Drug Abuse  
 1995 Organizing Committee, Fourth International Neurotrauma Meeting  
     Session  
 1996 Organizer, Conference, Jewish Biomedical Ethics: Comparison with  
     Christian and Secular Perspectives  
 1996 Session Chair: Neurobiology of CNS Injury, FASEB Symposium  
 1996 Chair, Fourth International Neurotrauma Meeting  
 1997 Program Committee, American Society for Experimental NeuroTherapeutics  
 1998- Study Section BDCN3, NINDS, NIH  
 1998 Session Chair, Fourth International Symposium on Neuroprotection  
 1998-1999 Organizing Committee, Fifth International Neurotrauma Meeting

2000- Organizing Committee, Sixth International Neurotrauma Meeting

### Service to Professional Publications

1987-88 Editorial Board, *CNS Trauma*  
 1987-97 Editorial Board, *Archives of Neurology*  
 1988- *Journal of Neurotrauma* Associate Editor (1988-95);  
 Section Editor, Molecular Neurobiology (1995-98)  
 1989- Editorial Board, *Res Comm Chem Path Pharmacol*  
 1996- Editorial Board, *Clinical Trials Advisor*

### **UNIVERSITY SERVICE (since 1991)**

#### Administrative Positions

Associate Dean for Biomedical Sciences, Graduate School (1991-95)  
 Dean of Research and Graduate Education, Medical School (1991-96)  
 Scientific Director, Medical Center (1991-96)  
 Director, M.D./Ph.D. Program (1992-97)  
 Director, Georgetown Institute for Cognitive and Computational Sciences (1995-98)  
 Chief, Division of Basic Neurosciences, Department of Neurology (1995-99)

#### University Committees

Chair, University Committee on Science  
 Computing and Networking Task Force  
 Chair, *Ad Hoc* Committee on Technology Transfer Policies  
 Chair, University Satellite Oversight Committee  
 Task Force for Environmental Science and Policy  
 Research Council of The Graduate School (*ex officio*)  
 Executive Committee of The Graduate School (*ex officio*)  
 Chair, Oversight Committee on Technology Transfer, Patents and Copyrights  
 Member, Search Committee, Executive Vice President, Georgetown University  
 Organizer, Noon Conversations on Jesuit Academic Perspective  
 External Review Committee, Department of Psychology

#### Medical Center Committees

Executive Faculty Committee  
 Medical Center Council  
 Chair, Committee on Computers in Research  
 Chair, Research Committee  
 Chair, Committee of Graduate Biomedical Program Directors  
 Chair, Graduate Advisory Committee  
 Chair, Task Force on Strategic Planning for Research and Graduate Education  
 Chair, Committee on GUMC-Veteran's Administration Interactions  
 Chair, *Ad Hoc* Committee on Establishing a Health Policy Institute  
 Steering Committee: Institute for Health Care Research & Policy  
 Steering Committee: Institute for Cardiovascular Sciences  
 Clinical Research Center Oversight Committee  
 Task Force on Clinical Research  
 Neuroscience Task Force  
 Search Committee for Director of Institute for Health Care Research and Policy  
 Search Committee for Chair of Neurosurgery  
 Search Committee for Chair of Ophthalmology  
 Search Committee for Chief, Division of Nephrology  
 Search Committee for Walters Chair in Cardiology  
 Search Committee for Director, Center for Molecular and Human Genetics

Search Committee for Chair, Department of Neurology (Chair)  
 Search Committee for Chair, Department of Radiology  
 Oversight Committee on GUMC-National Rehabilitation Hospital Interactions  
 Task Force to Reorganize Department of Microbiology  
 Task Force on Advanced Practices in Nursing Education  
 LCME Subcommittees: Financing; Graduate Education  
 Co-Chair, Perinatal Research Branch/Perinatal Research Facility (PRF)  
 Coordinating Committee; Member (*Ad Hoc*) PRF Scientific Review Committee  
 Group on Institutional Planning  
 Budget Restructuring Committee  
 Financial Stabilization Steering Committee  
 Faculty Research Planning Committee  
 Committee on Faculty  
 M.D./Ph.D. Advisory Committee  
 M.D./Ph.D. Admissions/Mentorship Committee  
 LCME Review Committee, Department of Pharmacology (Chair)

#### Department Committees

Education Committee (Chair)  
 Core Resources Committee

### **TEACHING ACTIVITIES**

Lectures in the following departments/courses (Georgetown, since July 1991)

Department of Physiology, Seminar Series  
 Introduction to Neuroscience Lectures  
 Co-Director, Neuroscience Survey Course  
 Department of Neurology, Grand Rounds  
 Department of Psychiatry, Grand Rounds  
 Department of Pediatrics, Seminar Series  
 Department of Emergency Medicine, Grand Rounds  
 Department of Anesthesia, Grand Rounds  
 Proseminar: Undergraduate Program in Cognitive Science  
 Interdisciplinary Research Survey Course  
 Neuropharmacology Course  
 Neuroscience Research Survey Course  
 Neurobiology Course, Medical School  
 Neuroscience Journal Club (Director)

#### Clinical

Department of Neurology (Ward Attending) (1 mo/yr); 1991-95  
 Professors Rounds, National Naval Medical Center (2 hrs/mo); 1992-95

#### Postdoctoral Fellows Supervised (since 1985)

1985-86	Brian Andrews, M.D.
1985	Kate Miller, M.D.
1985-86	Helen Engeseth, Ph.D.
1985-88	Robert Vink, Ph.D.
1986-87	Reizo Shirane, M.D.
1987-89	Matthias Lemke, M.D.
1987-89	Sabrina Yum, M.D.
1987-90	Scott Panter, Ph.D.
1987-91	Steven Graham, M.D., Ph.D.
1988-89	Robert Romhanyi, M.D.

1992-93	Virginia Ashby Sharpe, Ph.D.
1992-94	Fen-Yang Sun, Ph.D.
1992-95	Alexander Yakovlev, Ph.D.
1994-99	Susan Knoblach, Ph.D.
1994-97	Alexey Mukhin, Ph.D.
1994-99	Lei Fan, Ph.D.
1996-98	Gerard Fox, Ph.D.
1997-98	Svetlana Ivanova, Ph.D.
1998	Elena Kasanova, Ph.D.
1998	Yun Chen, Ph.D.
1998-2000	Renee Ren-Patterson, Ph.D.
1999-2001	Vilen Movsesyan, Ph.D.
1999-2000	Deirdre O'Leary, Ph.D.
1999-2001	Xiao Di, M.D., Ph.D.
1999-2001	Xiuling Huang, Ph.D.
1999-2000	Paul Mullins
1999-2000	Meredith Temple, Ph.D.
1999-2001	Wei-li Bao, M.B.B.S.
2000-2001	Maria Nikolaeva, Ph.D.
2000-	Paul Lea
2001-	Ibi Cernak, M.D., Ph.D.
2001-	Simone DiGiovanni, M.D., Ph.D.

#### Predoctoral Students Supervised

1995-98	Basil Eldadah (M.D./Ph.D. student)
1995-98	Jason Allen (M.D./Ph.D. student)
1998-2000	Rachelle Toman
1999-2000	Ali Al-Attar

#### Medical Students Supervised

1988-89	Rohit Bakshi
1989-90	Kimberly Clausen
1990-91	Heidi Gaspary
1996-97	Scott Imahara
2000-	Greg Wilde (five-year M.D. research track)

#### Undergraduate Students Supervised

1996-97	Sarah Pettrone
1997	Varun Kumar
1997-98	Ryan LeVasseur
1999-2001	Dan Calva
1999-2001	Jeff Van Gelderen
1999-2000	Alejandro Hidalgo
1999-2001	Sachin Mehta
1999	Miranda Russell

### GRANTS

#### Current Grants

1998-2001	The Role of Caspases in Apoptosis Induced by Traumatic Brain Injury, NIH R01 (Principal Investigator); <i>Total Direct Costs: \$443,621.</i>
2000-2003	Multipotential Drug Treatment Strategies, NIH R01 (Principal Investigator); <i>Total Direct Costs: \$856,276.</i>

- 1999-2002 Modulation of Traumatic Neuronal Injury by Metabotropic Glutamate Receptors, NIH R01 (Principal Investigator); *Total Direct Costs: \$571,682.*
- 2001-2002 Multidisciplinary Research Studies Relating to CNS Injury, Plasticity, and Treatment, USAMRDC (Principal Investigator); *Total Direct Costs: \$3,032,900.*

Prior Grants (since 1984)

- 2000-2001 Georgetown Institute for Cognitive and Computational Sciences, USAMRDC (Principal Investigator); *Total Direct Costs: \$3,810,000.*
- 1999-2000 Georgetown Institute for Cognitive and Computations Sciences, USAMRDC, (Principal Investigator); *Total Costs: \$4,012,000.*
- 1995-1999 Secondary Injury Factor and Preventative Treatment in CNS Trauma," Center for Disease Control (Principal Investigator); *Total Direct Costs: \$786,711.*
- 1993-1998 Georgetown Institute Cognitive and Computational Sciences (Principal Investigator); *Total Award: \$20,000,000.*
- 1995-96 Center for Molecular Genetics (Principal Investigator), Lucille P. Markey Trust Award, *\$1,000,000.*
- 1993-96 Multicenter Animal Spinal Cord Injury Study , NIH (R01) (Principal Investigator, Georgetown Component); *Costs for GU: Year 1 - \$119,940.*
- 1991-95 "Secondary Injury Factors and Preventative Treatment in CNS Trauma," Center for Disease Control (Principal Investigator); *Total Direct Costs: \$862,513.*
- 1990-95 "Excitotoxins, Bioenergetics, and Traumatic Brain Injury," NIH (R01) (Principal Investigator); *Total Direct Costs: \$665,862.*
- 1988-91 "NMR Metabolic Studies of Brain Ischemia and Reperfusion," NIH (R01) (Co-Investigator); *Total Direct Costs: \$558,675.*
- 1987-91 "Secondary Injury Factors and Preventive Treatment in Central Nervous System Trauma," Center for Disease Control (Principal Investigator); *Total Direct Costs: \$739,000.*
- 1987-90 Pathophysiology and Treatment of Secondary Spinal Cord Injury," VA Merit Review Proposal (Principal Investigator); *Total Direct Costs: \$251,000.*
- 1986-90 "Opioids, Opiate Receptors and Spinal Cord Injury," National Institutes of Health (R01) (Principal Investigator); *Total Direct Costs: \$220,000.*
- 1986-90 "Membrane Damage and Lipid Alterations in Spinal Cord Injury," Brain Edema Program Project Section, NIH (Principal Investigator); *Total Direct Costs: \$319,000.*
- 1986-89 "Endorphins and Catecholamines in Shock and Trauma," NIH (R01) (Co-Investigator); *Total Direct Costs: \$234,000.*
- 1986-89 "Opiate Antagonists in Traumatic Spinal Injury: Mechanism of Action," Brain Edema Program Project Section, NIH (Principal Investigator); *Total Direct Costs: \$241,000.*
- 1986-87 "Prospective Randomized Clinical Trial of TRH as a Therapy for Acute Spinal Cord Injury," Paralyzed Veterans of America (Co-Principal Investigator); *Total Direct Costs: \$82,000.*
- 1985-87 "Neuropeptides and Secondary Injury to the Central Nervous System: Basic Mechanisms," Office of Naval Research (Principal Investigator); *Total Direct Costs: \$110,000.*
- 1985-87 "Neuropeptides in Experimental Head Injury," United States Army Medical Research and Development Command (Principal Investigator); *Total Direct Costs: \$232,000.*
- 1984-87 "Pharmacological Therapies in Central Nervous System Injury," VA Merit Review Proposal (Principal Investigator); *Total Direct Costs: \$833,000.*



- 1984-86 "Spinal Cord Edema After Traumatic and Ischemic Spinal Cord Injury,"  
Brain Edema Program Project Section, NIH (Principal Investigator); *Total  
Direct Costs: \$105,000.*
- 1984 Department of Defense Instrumentation Grant (Principal Investigator);  
*\$87,000.*

## INVITED PAPERS, LECTURES, AND PRESENTATIONS

- 1978 American Public Health Association
- 1979 Infectious Disease Society of America, University of Oregon Health Sciences  
Center
- 1980 Brooke Army Medical Center (Burn Unit)  
Presbyterian University of Pennsylvania Medical Center  
National Institutes of Health  
University of South Alabama School of Medicine  
Indiana University School of Medicine  
University of California, San Francisco  
American Neurologic Association
- 1981 University of California, San Francisco  
Second Annual AMEDD Neurology Conference  
Society of Medical Consultants to the Armed Forces  
Paralysis Cure Research Foundation Conference  
New York University School of Medicine
- 1982 Medical College of Virginia  
National Institutes of Health  
University of Western Ontario  
University of California, San Diego  
Armed Forces Radiobiology Research Institute
- 1983 Howard University Medical School  
New York Academy of Sciences  
American Association of Neurological Surgeons  
Washington Veterans Administration Hospital  
George Washington University Medical School  
Brookings Institute  
University of Colorado School of Medicine  
Johns Hopkins University School of Medicine  
Letterman Army Institute of Research  
University of Massachusetts School of Medicine  
Massachusetts General Hospital  
Shriver Center  
University of Arizona School of Medicine  
Barrows Neurological Institute
- 1984 American Osteopathic Association (*Keynote Address*)  
First International Symposium on Central Nervous System Trauma  
Second International Symposium on the Spinal Cord (*Keynote Address*)  
University of Rochester School of Medicine  
The Neurological Institute, Columbia University School of Medicine  
American Neurological Association, Presidential Symposium  
Symposium on Mechanisms of Head and Spine Trauma

- 1985 University of Rochester School of Medicine  
University of Miami School of Medicine  
Stanford University School of Medicine  
Genentech, Incorporated  
University of California, Berkeley  
National Council for the Handicapped  
Third International Meeting on Brain-Heart Relationships  
Western Neurosurgical Society Meeting
- 1986 Federation of Western Societies of Neurological Science  
University of Rochester School of Medicine  
Regional Trauma Symposium, American Association of Neurological Surgeons  
University of Colorado School of Medicine  
American College of Emergency Physicians  
Society of Critical Care Medicine  
Brown University School of Medicine  
Towbes Foundation Conference on Thyrotropin Releasing Hormone  
Satellite Symposium, International Society of Hypertension  
Society of Neurosurgical Anesthesia and Neurologic Support Care  
(*Janssen Distinguished Lecturer*)  
University of Maryland School of Medicine  
University of Miami School of Medicine  
San Francisco Neurological Society
- 1987 University of Washington (*PVA Distinguished Lectureship*)  
San Francisco Neurological Society  
Children's Hospital Medical Center, San Francisco  
University of California, Davis (Martinez VAMC)  
CNS Trauma Symposium  
New York Academy of Sciences (TRH Symposium)  
American Paralysis Association Symposium  
Symposium on CNS Injury  
National Head Injury Foundation Symposium
- 1988 Symposium on Cellular and Molecular Correlates of CNS Trauma  
San Jose Hospital  
Genentech, Incorporated  
Society of Neurosurgical Anesthesia and Critical Care  
Neurological Disorders Symposium
- 1989 University of Miami School of Medicine  
University of California, San Diego  
Stanford Research Institute  
Centers for Disease Control  
Society of Neurological Spectroscopy  
International Coalition on Spinal Cord Injury  
San Francisco Neurological Society  
University of California, Davis
- 1990 Stanford University School of Medicine  
Duke University School of Medicine  
Georgetown University School of Medicine
- 1991 First International Neurotrauma Meeting, Fukushima, Japan  
University of Texas at Houston School of Medicine  
Children's Hospital, Washington, DC  
Johns Hopkins University School of Medicine

- 1993    Group on Institutional Planning, AAMC, Charleston, SC  
          University of South Carolina Medical Center, Charleston, SC  
          1993 NIH/Pharmaceutical Manufacturers Association Technology Transfer  
          Conference, Washington, DC  
          Second International Neurotrauma Meeting, Glasgow, Scotland
- 1994    National Naval Medical Center, Bethesda, MD  
          National Institute for Drug Abuse Conference, Baltimore, MD  
          Georgetown University Symposium "Ethical Issues of Animal Use in Research  
          and Education," Washington, DC
- 1995    Group on Institutional Planning, AAMC, Sanibel, FL  
          3rd International Neurotrauma Symposium, Toronto, Canada  
          Asilomar Conference on Spinal Cord Regeneration and Plasticity
- 1996    AAMC Business Group, Charleston, SC  
          NINDS, NIH  
          FASEB Conference: Neurobiology of CNS Injury  
          Philadelphia Neurological Society  
          University of Pennsylvania
- 1997    Wyeth Ayerst Pharmaceutical Corporation  
          American Academy of Neurology (Neuropharmacology Course)  
          8th International Symposium on Stroke, Neurotrauma and other Neurological  
          Disorders  
          4th International Neurotrauma Symposium, Seoul, South Korea  
          Shanghai Medical University, China  
          Military Medical Research Institute, Beijing, China
- 1998    Emory University  
          Israel Neurotrauma Society, Jerusalem, Israel  
          Merck-Frosst, Montreal, Canada  
          Neurotrauma Society  
          Fourth International Symposium on Neuroprotection, Annapolis, Maryland  
          NIH: NINDS
- 1999    International Symposium on Spinal Cord Injury, Aachen, Germany  
          Conference on Stroke Drug Development, Orlando, Florida  
          Merck-Frosst, Montreal, Canada  
          Krasnow Institute, George Mason University  
          Genentech, South San Francisco, California
- 2000    Medical College of Virginia  
          University of Maryland School of Medicine  
          University of Miami School of Medicine  
          National Neurotrauma Society, New Orleans, Louisiana  
          International Neurotrauma Society, Garmisch, Germany
- 2001    Winter Conference on Brain Research, Colorado  
          Children's Research Institute, Washington, D.C.  
          National Children's Medical Center, Washington, D.C.

## PUBLICATIONS

### Original Papers and Reviews (Refereed)

1. A.I. FADEN. Neurological sequelae of malignant external otitis. *Arch Neurol* 32: 204-205, 1975.
2. A.I. FADEN. Encephalopathy following treatment of chronic pulmonary failure. *Neurology* 26: 337-339, 1976.
3. A.I. FADEN, M.S. Globus, and J.P. Spire. Electroencephalographic changes following intra-amniotic prostaglandin F2a administration for therapeutic abortion. *Obstet Gynecol* 47: 607-608, 1976.
4. A.I. FADEN and J.J. Townsend. Myoclonus in Alzheimer's disease: A confusing sign. *Arch Neurol* 33: 278-280, 1976.
5. M.J. Aminoff, R.B. Layzer, S. Satya-Murti and A.I. FADEN. The declining electrical response of muscle to repetitive nerve stimulation in myotonia. *Neurology* 27: 812-816, 1977.
6. A.I. FADEN and D. Rollo. Persistently abnormal brain scintigraphy studies after cerebral infarction. *J Neurol* 215: 169-174. (Reproduced in 1978 Yearbook of Nuclear Medicine), 1977.
7. A.I. FADEN, J.P. Spire, and R. Faden. Fits, faints and the IUD. *Ann Neurol* 1: 305-306, 1977.
8. R. Faden and A.I. FADEN. False belief and the refusal of medical treatment. *J Med Ethics* 3: 133-136, 1977.
9. A.I. FADEN and R. Faden. Informed consent in medical practice: With particular reference to neurology. *Arch Neurol* 35: 761-764, 1978.
10. A.I. FADEN and J. Petras. An intraspinal sympathetic preganglionic pathway: Anatomic evidence in the dog. *Brain Res* 144: 358-362, 1978.
11. A.I. FADEN, T.P. Jacobs, M. Woods, and C.F. Tyner. Zona intermedia pressor sites in the cat spinal cord: right-left asymmetry. *Exp Neurol* 61: 571-582, 1978.
12. A.I. FADEN, T.P. Jacobs, and M. Woods. Cardioacceleratory sites in the zona intermedia of the cat spinal cord. *Exp Neurol* 61: 301-310, 1978.
13. R.A. Gravina, A.S. Nakanishi, and A.I. FADEN. Subacute sclerosing panencephalitis. *Am J Ophthalmol* 86: 106-109, 1978.
14. J.W. Holaday and A.I. FADEN. Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. *Nature* 275: 450-451, 1978.
15. R. Faden and A.I. FADEN. The ethics of health education as public health policy. *Health Educ Mono* 6:2, 1978.
16. J.M. Petras and A.I. FADEN. The origin of sympathetic preganglionic neurons in the dog. *Brain Res* 144: 353-357, 1978.
17. A.I. FADEN and J.W. Holaday. Opiate antagonists: A role in the treatment of hypovolemic shock. *Science* 205: 317-318, 1979.
18. A.I. FADEN, T.P. Jacobs, and J.W. Holaday. Naloxone alteration of physiologic parameters in spinally transected animals. *Trans Am Neurol Assoc* 104:157-161, 1979.
19. A.I. FADEN, M. Woods, and T.P. Jacobs. An intraspinal sympathetic preganglionic pathway: Physiologic evidence in the cat. *Brain Res* 162:13-20, 1979.
20. A.I. FADEN and J.W. Holaday. Naloxone treatment of endotoxin shock: Stereo-specificity of physiologic and pharmacologic effects in the rat. *J Pharmacol Exp Ther* 212: 441-447, 1980.
21. A.I. FADEN, T.P. Jacobs, and J.W. Holaday. Endorphin-parasympathetic interactions in spinal shock. *J Auton Nerv Syst* 2: 295-304, 1980.

22. A.I. FADEN and T.P. Jacobs. Cardiac contractility and the spinal sympathetic neuron. *Neurol Res* 1: 227-237, 1980.
23. J.W. Holaday and A.I. FADEN. Naloxone acts at central opiate receptors to reverse hypotension, hypothermia, and hypoventilation in spinal shock. *Brain Res* 189: 295-299, 1980.
24. D.G. Reynolds, N.J. Gurll, T. Vargish, R. Lechner, A.I. FADEN, and J.W. Holaday. Blockade of opiate receptors with Naloxone improves survival and cardiac performance in canine endotoxic shock. *Circ Shock* 7: 39-48, 1980.
25. T. Vargish, D.G. Reynolds, N.J. Gurll, R.B. Lechner, J.W. Holaday, and A.I. FADEN. Naloxone reversal of hypovolemic shock in dogs. *Circ Shock* 7: 31-38, 1980.
26. A.I. FADEN and J.W. Holaday. Experimental endotoxin shock: The pathophysiologic function of endorphins and treatment with opiate antagonists. *J Infect Dis* (Review) 142: 229-238, 1980.
27. A.I. FADEN, T.P. Jacobs, G. Feuerstein, and J.W. Holaday. Dopamine partially mediates the cardiovascular effects of Naloxone after spinal injury. *Brain Res* 213: 415-421, 1981.
28. A.I. FADEN, T.P. Jacobs, and J.W. Holaday. Opiate antagonist improves neurologic recovery after spinal injury. *Science* 211: 493-494, 1981.
29. A.I. FADEN, T.P. Jacobs, and J.W. Holaday. Thyrotropin-releasing hormone improves neurologic recovery after spinal trauma in cats. *N Eng J Med* 305:1063-1067, 1981.
30. A.I. FADEN, T.P. Jacobs, E.H. Mougey, and J.W. Holaday. Endorphins in experimental spinal injury: Therapeutic effect of Naloxone. *Ann Neurol* 10: 326-332, 1981.
31. A.I. FADEN and E. Mendoza. Peripheral sensorimotor neuropathy associated with chronic obstructive pulmonary disease: A prospective clinical and electrophysiologic study. *Arch Neurol* 38: 639-642, 1981.
32. R. Faden, C. Becker, C. Lewis, J.B. Freeman, and A.I. FADEN. Disclosure of information to patients in medical care. *Med Care* 19: 718-733, 1981.
33. R. Faden, C. Lewis, C. Becker, A.I. FADEN, and J.B. Freeman. Disclosure standards and informed consent. *J Health Politics Policy Law* 6: 255-284, 1981.
34. J.W. Holaday, R. D'Amato, and A.I. FADEN. Thyrotropin-releasing hormone improves cardiovascular function in experimental endotoxic and hemorrhagic shock. *Science* 213: 216-218, 1981.
35. J.W. Holaday, M. O'Hara, and A.I. FADEN. Hypophysectomy alters cardiorespiratory variables: Central effects of pituitary endorphins in shock. *Am J Physiol* 241: H479-H485, 1981.
36. J.W. Holaday, B.A. Ruvio, and A.I. FADEN. Thyrotropin-releasing hormone improves blood pressure and survival in endotoxic shock. *Eur J Pharmacol* 4: 101-105, 1981.
37. A.I. FADEN, P. Chan, and E. Mendoza. Progressive isolated segmental anhidrosis. *Arch Neurol* 39: 172-175, 1982.
38. A.I. FADEN, J.M. Hallenbeck, and C.Q. Brown. Treatment of experimental stroke: Comparison of Naloxone and thyrotropin releasing hormone. *Neurology* 32: 1083-1087, 1982.
39. A.I. FADEN, T.P. Jacobs, and J.W. Holaday. Comparison of early and late Naloxone treatment in experimental spinal injury. *Neurology* 32: 677-681, 1982.
40. G.Z. Feuerstein and A.I. FADEN. Differential cardiovascular effects of  $\mu$ ,  $\delta$ , and  $\kappa$  opiate agonists at discrete hypothalamic sites in the anesthetized rat. *Life Sci* 31: 2197-2200, 1982.
41. A.H. Hassen, G.Z. Feuerstein, and A.I. FADEN. Cardiovascular responses to opioid agonists injected into the nucleus tractus solitarius of anesthetized cats. *Life Sci* 31: 2193-2196, 1982.
42. A.H. Hassen, G.Z. Feuerstein, and A.I. FADEN.  $\mu$  receptors and opioid cardiovascular effects in the NTS of the rat. *Peptides* 3: 1031-1037, 1982.

43. A.H. Hassen, G.Z. Feuerstein, A. Pfeiffer, and A.I. FADEN. Delta versus mu receptors receptors: Cardiovascular and respiratory effects of opiate agonists micro-injected into nucleus tractus solitarius of cats. *Reg Peptides* 4: 299-309, 1982.
44. C.J. Molineaux, G.Z. Feuerstein, A.I. FADEN, and B.M. Cox. Distribution of immunoreactive dynorphin in discrete brain nuclei: Comparison with vasopressin. *Neurosci Lett* 3: 170-184, 1982.
45. Pfeiffer, G.Z. Feuerstein, A.I. FADEN, and I.J. Kopin. Evidence for an involvement of  $\mu$ - but not  $\Delta$ - or  $\kappa$ -opiate receptors in sympathetically and parasympathetically mediated cardiovascular responses to opiates upon intrahypothalamic microinjection. *Life Sci* 31: 1279-1282, 1982.
46. A.I. FADEN and G. Feuerstein. Hypothalamic regulation of the cardiovascular and respiratory systems: Role of specific opiate receptors. *Br J Pharmacol* 79: 997-1002, 1983.
47. A.I. FADEN and T.P. Jacobs. Dynorphin induces partially reversible paraplegia in the rat. *Eur J Pharmacol* 91: 321-324, 1983.
48. A.I. FADEN, T.P. Jacobs, G.P. Smith, G. Green, and J. Zivin. Neuropeptides in spinal cord injury: Comparative experimental models. *Peptides* 4: 631-634, 1983.
49. A.I. FADEN, T.P. Jacobs, M.T. Smith, and J.W. Holaday. Comparison of thyrotropin releasing hormone (TRH), Naloxone and dexamethasone treatments in experimental spinal injury. *Neurology* 33: 673-678, 1983.
50. A.I. FADEN, T.P. Jacobs, and J.A. Zivin. Comparison of Naloxone and a  $\delta$ -selective antagonist in experimental spinal stroke. *Life Sci* 33 (Suppl 1): 707-710, 1983.
51. G. Feuerstein and A.I. FADEN. Central autonomic effects of dermorphin in conscious rats. *J Pharmacol Exp Ther* 226:151-156, 1983.
52. Feuerstein and A.I. FADEN. Dermorphin: Cardiovascular and sympathetic modulation in the anteroventral hypothalamus of conscious rats. *Life Sci* (Suppl 1) 33: 731-734, 1983.
53. G. Feuerstein, A.H. Hassen, and A.I. FADEN. TRH: Cardiovascular and sympathetic modulation in brain nuclei of the rat. *Peptides* 4: 617-620, 1983.
54. G. Feuerstein, C. Molineaux, J. Rosenberger, A.I. FADEN, and B. Cox. Dynorphin and leu-enkephalin in brain nuclei and pituitary of WKY and SHR rats. *Peptides* 4: 225-229, 1983.
55. G. Feuerstein, R. Zerbe, and A.I. FADEN. Opiate receptors and cardiovascular control in conscious SHR and WKY rats. *Hypertension* 5: 663-671, 1983.
56. G. Feuerstein, Z. Zukowska-Grojec, M. Bayorh, I.J. Kopin, and A.I. FADEN. Leukotriene D<sub>4</sub>-induced hypotension is reversed by thyrotropin-releasing hormone. *Prostaglandins* 26: 711-724, 1983.
57. S.C. Gilman, M.J. Ackerman, J.M. Hallenbeck, and A.I. FADEN. Failure of Naloxone or  $\beta$ -endorphin to affect pressure-induced tremor in the guinea pig. *Undersea Biomed Res* 10: 89-93, 1983.
58. J.M. Hallenbeck, T.P. Jacobs, and A.I. FADEN. Combined PGI<sub>2</sub>, indomethacin and heparin improves neurological recovery after spinal trauma in cats. *J Neurosurg* 58: 749-754, 1983.
59. A.H. Hassen, G. Feuerstein, and A.I. FADEN. Differential cardiovascular effects mediated by  $\mu$  and  $\kappa$  opiate receptors in hindbrain nuclei. *Peptides* 4: 621-625, 1983.
60. J.W. Holaday, R.J. D'Amato, B.A. Ruvio, G. Feuerstein, and A.I. FADEN. Adrenalectomy blocks pressor responses to Naloxone in endotoxic shock: Evidence for sympathomedullary involvement. *Circ Shock* 11: 201-210, 1983.
61. J.W. Holaday and A.I. FADEN. Thyrotropin-releasing hormone: Autonomic effects upon cardiorespiratory function in endotoxic shock. *Reg Peptides* 7: 125, 1983.
62. J.W. Holaday, G.W. Pasternak, R.J. D'Amato, B.A. Ruvio, and A.I. FADEN. Naloxone lacks therapeutic effects in endotoxic shock yet blocks the effects of Naloxone. *Eur J Pharmacol* 89: 293-296, 1983.

63. J.W. Holaday, G.W. Pasternak, and A.I. FADEN. Naloxazone pretreatment modifies cardiorespiratory, temperature and behavioral effects of morphine. *Neurosci Lett* 37: 199-204, 1983.
64. W.E. Lux, Jr., G. Feuerstein, and A.I. FADEN. Alteration of leukotriene D4 hypotension by thyrotropin-releasing hormone. *Nature* 302: 82-824, 1983.
65. W.E. Lux, Jr., G.Z. Feuerstein, and A.I. FADEN. Thyrotropin-releasing hormone reverses the hypotension and bradycardia produced by leukotriene D4 in unanesthetized guinea pigs. *Prostag Leukot Med* 10: 301-308, 1983.
66. W.E. Lux, Jr., G. Feuerstein, and A.I. FADEN. Thyrotropin-releasing hormone reverses experimental anaphylactic shock through non-endorphin-related mechanisms. *Eur J Pharmacol* 90: 301-302, 1983.
67. Pfeiffer, G. Feuerstein, I.J. Kopin, and A.I. FADEN. Cardiovascular and respiratory effects of  $\mu$ -,  $\delta$ - and  $\kappa$ -opiate agonists microinjected into the anterior hypothalamic brain area of awake rats. *J Pharmacol Exp Ther* 225: 735-741, 1983.
68. Pfeiffer, G. Feuerstein, R.L. Zerbe, A.I. FADEN, and I.J. Kopin.  $\mu$  receptors mediate opioid cardiovascular effects at anterior hypothalamic sites through sympathoadrenomedullary and parasympathetic pathways. *Endocrinology* 113: 929-938, 1983.
69. R.L. Zerbe, S. Kirtland, A.I. FADEN, and G. Feuerstein. Central cardiovascular effects of mammalian neurohypophyseal peptides in conscious rats. *Peptides* 4: 627-630, 1983.
70. A.I. FADEN. Neuropeptides and stroke: Current status and potential application. *Stroke* (Review) 14: 169-172, 1983.
71. A.I. FADEN. Opiate antagonists in the treatment of stroke. *Curr Concepts Cerebrovasc Dis* (Review) 18: 27-31, 1983.
72. A.I. FADEN. Recent pharmacological advances in experimental spinal injury: Theoretical and methodological considerations. *Trends Neurosci* (Review) 6: 375-377, 1983.
73. A.I. FADEN. Opiate antagonists and thyrotropin-releasing hormone: I. Potential role in the treatment of shock. *JAMA* (Review) 252: 1177-1180, 1984.
74. A.I. FADEN. Opiate antagonists and thyrotropin-releasing hormone: II. Potential role in the treatment of central nervous system injury. *JAMA* (Review) 252: 1452-1454, 1984.
75. A.I. FADEN. Endogenous opioids: Physiologic and pathophysiologic actions. *J Am Osteopath Assoc* (Review) 84 (Suppl. 1): 129-134, 1984.
76. A.I. FADEN and T.P. Jacobs. Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action. *Br J Pharmacol* 81: 271-276, 1984.
77. A.I. FADEN, T.P. Jacobs, D.H. Patrick, and M.T. Smith. Megadose corticosteroid therapy following experimental traumatic spinal injury. *J Neurosurg* 60: 712-716, 1984.
78. A.I. FADEN, T.P. Jacobs, and M.T. Smith. Evaluation of the calcium channel antagonist nimodipine in experimental spinal cord ischemia. *J Neurosurg* 60: 796-799, 1984.
79. G. Feuerstein, A.I. FADEN, and S.A. Krumins. Alteration in opiate receptor binding after hemorrhagic shock. *Eur J Pharmacol* 100: 245-246, 1984.
80. G. Feuerstein, C. Helke, and A.I. FADEN. Differential changes in substance P and somatostatin in brain nuclei of rats exposed to hemorrhagic shock. *Brain Res* 300: 305-310, 1984.
81. G. Feuerstein, A.K. Johnson, R.L. Zerbe, R. Davis-Kramer, and A.I. FADEN. Anteroventral hypothalamus and hemorrhagic shock: Cardiovascular and neuroendocrine responses. *Am J Physiol* 246:R551-R557, 1984.
82. G. Feuerstein, R.L. Zerbe, and A.I. FADEN. Central cardiovascular effects of vasotocin, oxytocin and vasopressin in conscious rats. *J Pharmacol Exp Ther* 228: 348-353, 1984. A.H. Hassen, G. Feuerstein, and A.I. FADEN.  $\delta$  opioid receptors modulate cardiorespiratory function in hindbrain nuclei of rat. *J Neurosci* 4: 2213-2221, 1984.
83. A.H. Hassen, G. Feuerstein, and A.I. FADEN. Selective cardiorespiratory effects mediated by  $\mu$ -opioid receptors in the nucleus ambiguus. *Neuropharmacol* 23: 407-415, 1984.

84. Pfeiffer, D. Pfeiffer, G. Feuerstein, A.I. FADEN and I.J. Kopin. An increase in opiate receptor-sites is associated with enhanced cardiovascular depressant, but not respiratory depressant action of morphine. *Brain Res* 296: 305-311, 1984.
85. A.I. FADEN, T.P. Jacobs, and M.T. Smith. Thyrotropin-releasing hormone in experimental spinal injury: Dose response and late treatment. *Neurology* 34: 1280-1284, 1984.
86. A.I. FADEN, T.P. Jacobs, M.T. Smith, and J.A. Zivin. Naloxone in experimental spinal cord ischemia: Dose response studies. *Eur J Pharmacol* 103: 115-120, 1984.
87. W.E. Lux, Jr., G. Feuerstein, and A.I. FADEN. Effects of thyrotropin-releasing hormone (TRH) on lipoxigenase-induced hypotension in the unanesthetized guinea pig. *Pharm Res* 3: 135-137, 1984.
88. G. Feuerstein, W.E. Lux, Jr., F. Snyder, D. Ezra, and A.I. FADEN. Hypotension produced by platelet-activating factor is reversed by thyrotropin-releasing hormone. *Circ Shock* 13: 255-260, 1984.
89. G. Feuerstein, D. Lozovsky, L.A. Cohen, V.M. Labroo, K.L. Kirk, I.J. Kopin, and A.I. FADEN. Differential effect of fluorinated analogs of TRH on the cardiovascular system and prolactin release. *Neuropeptides* 4: 303-310, 1984.
90. G.Z. Feuerstein, W.E. Lux, Jr., D. Ezra, and A.I. FADEN. Reversal of leukotriene hypotension by thyrotropin releasing hormone. *Neurosci Res* 2: 121-124, 1984.
91. G. Feuerstein, C.J. Molineaux, J.G. Rosenberger, R.L. Zerbe, B.M. Cox, and A.I. FADEN. Effect of hemorrhage on vasopressin, dynorphin A and leu5-enkephalin in the hypothalamopituitary system of the rat. *Clin Exp Hyperten* A6: 1973-1976, 1984.
92. G. Feuerstein and A.I. FADEN. Cardiovascular effects of dynorphin A-(1-8), dynorphin A-(1-3) and dynorphin A-(1-17) microinjected into the preoptic medialis nucleus of the rat. *Neuropeptides* 5: 295-298, 1984.
93. B.M. Cox, C.J. Molineaux, T.P. Jacobs, J.G. Rosenberger, and A.I. FADEN. Effects of traumatic injury on dynorphin immunoreactivity in spinal cord. *Neuropeptides* 5: 571-574, 1985.
94. A.I. FADEN, S. Knoblach, C. Mays, and T.P. Jacobs. Motor dysfunction after spinal cord injury is mediated by opiate receptors. *Peptides* 6 (Suppl. 1): 15-17, 1985.
95. G. Feuerstein, E. Powell, and A.I. FADEN. Central effects of  $\mu$ -,  $\Delta$ - and  $\kappa$ -receptor agonists in hemorrhagic shock. *Peptides* 6 (Suppl. 1) 13, 1985.
96. A.I. FADEN, C.J. Molineaux, J.G. Rosenberger, T.P. Jacobs, and B.M. Cox. Increased dynorphin immunoreactivity in spinal cord after traumatic injury. *Reg Peptides* 11: 35-41, 1985.
97. G. Feuerstein, W.E. Lux, Jr., D. Ezra, E.C. Hayes, F. Snyder, and A.I. FADEN. Thyrotropin-releasing hormone blocks the hypotensive effects of platelet activating factor in the unanesthetized guinea pig. *J Cardiovasc Pharmacol* 7: 335-340, 1985.
98. N. Zamir, D. Zamir, L. Eiden, M. Palkovits, M.J. Brownstein, R. Eskay, E. Weber, A.I. FADEN, and G. Feuerstein. Methionine- and leucine-enkephalin in rat neurohypophysis: Different responses to osmotic stimuli and T-2 toxin. *Science* 228: 604-608, 1985.
99. Feuerstein, D. Goldstein, P.W. Ramwell, R.L. Zerbe, W. Lux, Jr., A.I. FADEN, and M.A. Bayorh. Cardiorespiratory, sympathetic and biochemical responses to T-2 toxin in the guinea pig and rat. *J Pharmacol Exp Ther* 232: 786-794, 1985.
100. S.A. Krumins, A.I. FADEN, and G. Feuerstein. Opiate binding in rat hearts: modulation of binding after hemorrhagic shock. *Biochem Biophys Res Commun* 127: 120-128, 1985.
101. M.A. Bayorh, A.I. FADEN, and G. Feuerstein. Differential hemodynamic effects of leukotriene D4 in anesthetized rats: Evaluation by directional pulsed Doppler technique. *Prostag Leukot Med* 17: 229-241, 1985.
102. A.I. FADEN and T.P. Jacobs. Opiate antagonist WIN44,441-3 stereospecifically improves neurologic recovery after ischemic spinal injury. *Neurology* 35: 1311-1315, 1985.



103. A.I. FADEN and T.P. Jacobs. Effect of TRH analogs on neurologic recovery after experimental spinal trauma. *Neurology* 35:1331-1334, 1985.
104. A.I. FADEN, C.J. Molineaux, J.G. Rosenberger, T.P. Jacobs, and B.M. Cox. Endogenous opioid immunoreactivity in rat spinal cord following traumatic injury. *Ann Neurol* 17: 386-390, 1985.
105. A.I. FADEN, T.P. Jacobs, and C.J. Helke. Changes in substance P and somatostatin in the spinal cord after traumatic spinal injury in the rat. *Neuropeptides* 6: 215-225, 1985.
106. G. Feuerstein, M.A. Bayorh, R.E. Stull, D.S. Goldstein, R.L. Zerbe, P.W. Ramwell, and A.I. FADEN. Effects of nafazatrom on cardiovascular, sympathetic, and endocrine responses to hemorrhagic shock in conscious rats. *Circ Shock* 17: 223-232, 1985.
107. J. Eimerl, M.A. Bayorh, Z. Zukowska-Grojec, A.I. FADEN, D. Ezra, and G. Feuerstein. Substance K: Vascular and cardiac effects in rat and pig. *Peptides* 6 (Suppl. 2): 149-153, 1985.
108. A.I. FADEN. New pharmacological approaches to spinal cord injury: Opiate antagonists and thyrotropin-releasing hormone. *CNS Trauma* (Review) 2: 5-8, 1985.
109. T. Hokfelt, L. Skirboll, B. Everett, B. Meister, M. Brownstein, T. Jacobs, A. FADEN, S. Kaga, M. Goldstein, R. Markstein, G. Dockray, and J. Rehfeld. Distribution of cholecystinin-like immunoreactivity in the nervous system with special reference to coexistence with classical neurotransmitters and other neuropeptides. *Ann NY Acad Sci* 448: 255-274, 1985.
110. T.K. McIntosh and A.I. FADEN. Thyrotropin-releasing hormone and circulatory shock. *Circ Shock* (Review) 18: 241-258, 1986.
111. T.K. McIntosh and A.I. FADEN. Opiate antagonists in traumatic shock. *Ann Emerg Med* (Review) 15: 1462-1465, 1986.
112. S.A. Krumins and A.I. FADEN. Traumatic injury alters opiate receptor binding in rat spinal cord. *Ann Neurol* 19: 498-501, 1986.
113. A.I. FADEN, N.S. Pilotte, and D.R. Burt. Experimental spinal cord injury: Effects of trauma or ischemia on TRH and muscarinic receptors. *Neurology* 36: 723-736, 1986.
114. A.I. FADEN, T.G. Hill, and M. Kubek. Changes in TRH immunoreactivity in spinal cord after experimental spinal injury. *Neuropeptides* 7:11-18, 1986.
115. A.I. FADEN. Neuropeptides and central nervous system injury: Clinical implications. *Arch Neurol* 43: 501-504, 1986.
116. A.I. FADEN, P.H. Chan, and S. Longar. Alterations in lipid metabolism, (Na<sup>+</sup>,K<sup>+</sup>)-ATPase activity, and tissue water content of spinal cord following experimental traumatic injury. *J Neurochem* 48: 1809-1816, 1987.
117. R. Vink, T.K. McIntosh, and A.I. FADEN. Metabolic changes following central nervous system trauma as determined by *in vivo* magnetic resonance spectroscopy. *US Med* 23: 20, 1987.
118. R. Vink, T.K. McIntosh, M.W. Weiner, and A.I. FADEN. Effects of traumatic brain injury on cerebral high-energy phosphates and pH: A <sup>31</sup>P magnetic resonance spectroscopy study. *J Cereb Blood Flow Metab* 7: 563-571, 1987.
119. T.K. McIntosh, A.I. FADEN, M.R. Bendall, and R. Vink. Traumatic brain injury in the rat: Alteration in brain lactate and pH as characterized by <sup>1</sup>H and <sup>31</sup>P NMR. *J Neurochem* 49: 1530-1540, 1987.
120. M. Lemke, P. Demediuk, T.K. McIntosh, R. Vink, and A.I. FADEN. Alterations in tissue Mg<sup>2+</sup>, Na<sup>+</sup> and spinal cord edema following impact trauma in rats. *Biochem Biophys Res Commun* 147: 1170-1175, 1987.
121. T.K. McIntosh, R.L. Hayes, D.S. DeWitt, V. Agura, and A.I. FADEN. Endogenous opioids may mediate secondary damage after experimental brain injury. *Am J Physiol* 253: E565-E574, 1987.

122. R. Vink, S.M. Knoblach, and A.I. FADEN.  $^{31}\text{P}$  magnetic resonance spectroscopy of traumatic spinal cord injury. *Magn Res Med* 5: 390-394, 1987.
123. T.K. McIntosh, L. Noble, B. Andrews, and A.I. FADEN. Traumatic brain injury in the rat: Characterization of a midline fluid percussion model. *CNS Trauma* 4: 119-134, 1987.
124. R. Vink, T.K. McIntosh, P. Demediuk, and A.I. FADEN. Decrease in total and free magnesium concentration following traumatic brain injury in rats. *Biochem Biophys Res Comm* 149: 594-599, 1987.
125. A.I. FADEN, A.E. Takemori, P.S. Portoghese.  $\kappa$ -Selective opiate antagonist norbinaltorphimine improves outcome after traumatic spinal cord injury in rats. *CNS Trauma* 4: 227-237, 1987.
126. T.K. McIntosh, V.A. Head, and A.I. FADEN. Alterations in regional concentrations of endogenous opioids following traumatic brain injury in the cat. *Brain Res* 425: 225-233, 1987.
127. A.I. FADEN. Pharmacotherapy in spinal cord injury: A critical review of recent developments. *Clin Neuropharm* (Review) 10:193-204, 1987.
128. A.I. FADEN. Opiate-receptor antagonists, thyrotropin-releasing hormone (TRH) and TRH analogs in the treatment of spinal cord injury. *CNS Trauma* (Review) 4: 217-226, 1987.
129. R. Vink, T.K. McIntosh, S. Fernyak, M.W. Weiner, and A.I. FADEN. Proton and phosphorous NMRI studies of traumatic brain injury in rats. *Ann NY Acad Sci* 508: 497-500, 1988.
130. R. Vink, T.K. McIntosh, P. Demediuk, M. Weiner, A.I. FADEN. Decline in intracellular free  $\text{Mg}^{2+}$  is associated with irreversible tissue injury after brain trauma. *J Biol Chem* 263: 757-761, 1988.
131. A.I. FADEN, I. Sacksen, and L.J. Noble. Structure-activity relationships of TRH analogs in experimental spinal cord injury. *Brain Res* 448: 287-293, 1988.
132. A.I. FADEN, A. Gannon, and A.I. Basbaum. Use of serotonin immunocytochemistry as a marker of injury severity after experimental spinal trauma in rats. *Brain Res* 450: 94-100, 1988.
133. B.T. Andrews, P.R. Weinstein, and A.I. FADEN. Computerized cortical surface electroencephalography after temporary middle cerebral artery occlusion in rabbits. *Neurosurgery* 22: 681-686, 1988.
134. A.I. FADEN, M. Lemke, R.P. Simon, and L.J. Noble. *N*-methyl-D-aspartate antagonist MK801 improves outcome following traumatic spinal cord injury in rats: Behavioral, anatomic and neurochemical studies. *J Neurotrauma* 5: 33-45, 1988.
135. A.I. FADEN, L. Sacksen, and L.J. Noble. Opiate-receptor antagonist Nalmefene improves neurological recovery after traumatic spinal cord injury in rats. *J Pharmacol Exp Ther* 245: 742-748, 1988.
136. A.I. FADEN and R.P. Simon. A potential role for excitotoxins in the pathophysiology of spinal cord injury. *Ann Neurol* 23: 623-626, 1988.
137. R. Vink, T.K. McIntosh, I. Yamakami, and A.I. FADEN.  $^{31}\text{P}$  NMR characterization of graded traumatic brain injury in rats. *Magn Res Med* 6: 37-48, 1988.
138. T.K. McIntosh, R. Vink, and A.I. FADEN. An analogue of thyrotropin-releasing hormone improves outcome after brain injury:  $^{31}\text{P}$  NMR studies. *Am J Physiol* 254: R785-R792, 1988.
139. P. Demediuk and A.I. FADEN. Traumatic spinal cord injury in rats causes increases in tissue thromboxane but not peptidoleukotrienes. *J Neurosci* 20: 115-121, 1988.
140. A.I. FADEN, M. Lemke, and P. Demediuk. Effects of BW755C, a mixed cyclo-oxygenase-lipoxygenase inhibitor, following traumatic spinal cord injury in rats. *Brain Res* 463: 63-68, 1988.
141. R. Vink, T.K. McIntosh, and A.I. FADEN. Non-edited  $^1\text{H}$  NMR lactate/*n*-acetyl aspartate ratios for *in vivo* determination of lactate concentration in brain. *Magn Res Med* 7: 95-99, 1988.

142. R. Vink, T.K. McIntosh, and A.I. FADEN. Treatment with the thyrotropin-releasing hormone analog CG3703 restores magnesium homeostasis following traumatic brain injury in rats. *Brain Res* 460: 184-188, 1988.
143. T.K. McIntosh, A.I. FADEN, I. Yamakami, and R. Vink. Magnesium deficiency exacerbates and pretreatment improves outcome following traumatic brain injury in rats:  $^{31}\text{P}$  magnetic resonance spectroscopy and behavioral studies. *J Neurotrauma* 5: 17-31, 1988.
144. B.T. Andrews, T.K. McIntosh, M.G. Gonzalez, P. Weinstein, and A.I. FADEN. Levels of endogenous opioids and effects of an opiate antagonist during regional cerebral ischemia in rats. *J Pharmacol Exp Ther* 247: 1248-1254, 1988.
145. R. Vink, A.I. FADEN, and T.K. McIntosh. Changes in cellular bioenergetic state following graded traumatic brain injury in rats: Determination by  $^{31}\text{P}$  phosphorus magnetic resonance spectroscopy. *J Neurotrauma* 5: 315-330, 1988.
146. R. Vink, L.J. Noble, S.M. Knoblach, M.R. Bendall, and A.I. FADEN. Metabolic changes in rabbit spinal cord after trauma: Magnetic resonance spectroscopy studies. *Ann Neurol* 25: 26-31, 1989.
147. A.I. FADEN. TRH analog YM-14673 improves outcome following traumatic brain and spinal cord injury in rats: Dose response studies. *Brain Res* 486: 228-235, 1989.
148. A.I. FADEN, P. Demediuk, S. Panter, and R. Vink. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. *Science* 244: 798-800, 1989.
149. T.K. McIntosh, R. Vink, I. Yamakami, and A.I. FADEN. Magnesium protects against neurological deficit after brain injury. *Brain Res* 482: 252-260, 1989.
150. P. Demediuk, M.P. Daly, and A.I. FADEN. Effect of impact trauma on neurotransmitter and non-neurotransmitter amino acids in rat spinal cord. *J Neurochem* 52: 1529-1536, 1989.
151. T.K. McIntosh, R. Vink, L. Noble, I. Yamakami, S. Fernyak, and A.I. FADEN. Traumatic brain injury in the rat: Characterization of a lateral fluid-percussion model. *Neuroscience* 28: 233-244, 1989.
152. R. Vink, S. Yum, M. Lemke, P. Demediuk, and A.I. FADEN. Traumatic spinal cord injury in rabbits decreases intracellular free magnesium concentration as measured by  $^{31}\text{P}$  MRS. *Brain Res* 490: 144-147, 1989.
153. A.I. FADEN. Opioid and non-opioid mechanisms may contribute to dynorphin's pathophysiological actions in spinal cord injury. *Ann Neurol* 27: 67-74, 1990.
154. R. Bakshi and A.I. FADEN. Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis. *Brain Res* 507: 1-5, 1990.
155. S.S. Panter, S.W. Yum, and A.I. FADEN. Alteration in extracellular amino acids after traumatic spinal cord injury. *Ann Neurol* 27: 96-99, 1990.
156. M. Lemke, B. Frei, B.N. Ames, and A.I. FADEN. Decreases in tissue levels of ubiquinol-9 and -10, ascorbate and alpha-tocopherol following spinal cord impact trauma in rats. *Neurosci Lett* 108: 201-206, 1990.
157. S. Yum and A.I. FADEN. Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia. *Arch Neurol* 47: 277-281, 1990.
158. M. Lemke and A.I. FADEN. Edema development and ion changes in rat spinal cord after impact trauma: Injury dose-response studies. *J Neurotrauma* 7: 41-54, 1990.
159. R. Bakshi and A.I. FADEN. Blockade of the glycine modulatory site of NMDA receptors modifies dynorphin-induced behavioral effects. *Neurosci Lett* 110: 113-117, 1990.
160. S.H. Graham, K. Shiraishi, S.S. Panter, R.P. Simon, and A.I. FADEN. Changes in extracellular amino acid neurotransmitters produced by focal cerebral ischemia. *Neurosci Lett* 110: 124-130, 1990.
161. R. Vink, V.A. Head, P.J. Rogers, T.K. McIntosh, and A.I. FADEN. Mitochondrial metabolism following traumatic brain injury in rats. *J Neurotrauma* 7: 21-27, 1990.

162. A.I. FADEN, J.A. Ellison, and L.J. Noble. Effects of competitive and noncompetitive NMDA antagonists in spinal cord injury. *Eur J Pharmacol* 175:165-174, 1990.
163. A.I. FADEN, S.W. Yum, M. Lemke, and R. Vink. Effects of TRH-analog treatment on tissue cations, phospholipids and energy metabolism after spinal cord injury. *J Pharmacol Exp Ther* 255: 608-614, 1990.
164. A.I. FADEN, R. Shirane, L.-H. Chang, T.L. James, M. Lemke, and P.R. Weinstein. Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats. *J Pharmacol Exp Ther* 255: 451-458, 1990.
165. R. Bakshi, A.H. Newman, and A.I. FADEN. Dynorphin A-(1-17) induces alterations in free fatty acids, excitatory amino acids, and motor function through an opiate receptor-mediated mechanism. *J Neurosci* 10: 3793-3800, 1990.
166. M. Lemke, S.W. Yum, and A.I. FADEN. Lipid alterations correlate with tissue magnesium decrease following impact trauma in rabbit spinal cord. *Molec Chem Neuropath* 12(3):147-165, 1990.
167. R. Vink, T.K. McIntosh, R. Romhanyi, and A.I. FADEN. Opiate antagonist nalmefene improves intracellular free  $Mg^{2+}$ , bioenergetic state and neurologic outcome following traumatic brain injury in rats. *J Neurosci* 10: 3524-3530, 1990.
168. R. Vink, P. S. Portoghesi and A.I. FADEN. Kappa-opioid antagonist improves cellular bioenergetics and recovery after traumatic brain injury. *Am J Physiol* 261:R1527-1532, 1991.
169. A.I. FADEN and S. Salzman. Pharmacological strategies in CNS trauma. *Trends in Pharmacol Sci* 13(1):29-35, 1992.
170. A.I. FADEN. Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism. *J Neurosci* 12(2):425-429, 1992.
171. Panter, S. and A.I. FADEN. Pretreatment with NMDA antagonists limits release of excitatory amino acids following traumatic brain injury. *Neurosci Lett* 136:165-168, 1992.
172. Bakshi, R., R. Ni and A.I. FADEN. N-methyl-D-aspartate and opioid receptors mediate dynorphin-induced spinal cord injury. *Brain Res* 580:255-264, 1992.
173. A.I. FADEN and P. Halt. Platelet-activating factor reduces spinal cord blood flow and causes behavioral deficits after intrathecal administration in rats through a specific receptor mechanism. *Jour Pharm Exp Ther* 261(3):1064-1070, 1992.
174. Widmer, H. Abiko, A.I. FADEN, T. L. James and P. R. Weinstein. Effects of hyperglycemia on the time course of changes in energy metabolism and pH during global cerebral ischemia and reperfusion in rats: correlation of  $^1H$  and  $^{31}P$  NMR spectroscopy with fatty acid and excitatory amino acid levels. *J Cereb Blood Flow Metab* 12:456-468, 1992.
175. L.H. Chang, H. Shimizu, H. Abiko, R.A. Swanson, A.I. FADEN, T.L. James, and P.R. Weinstein. Effect of dichloroacetate on recovery of brain lactate, phosphorus energy metabolites, and glutamate during reperfusion after complete cerebral ischemia in rats. *J Cereb Blood Flow Metab* 12:1030-1038, 1992.
176. A.I. FADEN and P.A. Tzendzalian. Platelet-activating factor antagonists limit glycine changes and behavioral deficits after brain trauma. *Am J Physiol* 263:R909-R914, 1992.
177. P.Halt, R. Swanson and A.I. FADEN. Alcohol exacerbates behavioral and neurochemical effects of rat spinal cord trauma. *Arch Neurol* 49:1178-1184, 1992.
178. A.I. FADEN. Comparison of single and combination drug treatment strategies in experimental brain trauma. *J Neurotrauma* 10(2):91-100, 1993.
179. A.I. FADEN, V.M. Labroo and L.A. Cohen. Imidazole-substituted analogues of TRH limit behavioral deficits after experimental brain trauma. *J Neurotrauma* 10(2):101-108, 1993.

180. Shimizu, S.H. Graham, L.-H. Chang, J. Minotovitch, T.L. James, A.I. FADEN and P.R. Weinstein. Relationship between extracellular neurotransmitter amino acids and energy metabolism during cerebral ischemia in rats monitored by microdialysis and in vivo magnetic resonance spectroscopy. *Brain Res* 605:33-42, 1993.
181. A.I. FADEN. Experimental neurobiology of central nervous system injury. *Crit Rev Neurobiol* 7:175-186, 1993.
182. S.H. Graham, H. Shimizu, A. Newman, P. Weinstein, and A.I. FADEN. Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia. *Brain Res* 632:346-350, 1993.
183. T.K. McIntosh, S. Fernyak, R.L. Hayes and A.I. FADEN. Beneficial effect of the nonselective opiate antagonist Naloxone hydrochloride and the thyrotropin-releasing hormone (TRH) analog YM-14673 on long-term neurobehavioral outcome following experimental brain injury in the rat. *J Neurotrauma* 10:373-384, 1993.
184. C.C. Hanstock, A.I. FADEN, M.R. Bendall and R. Vink. Diffusion-weighted imaging differentiates ischemic tissue from traumatized tissue. *Stroke*, 25:843-848, 1994.
185. T.K. McIntosh, S. Fernyak, I. Yamakami, and A.I. FADEN. Centrally and systemically-administered kappa opioid agonists exacerbate cardiovascular and neurobehavioral response to traumatic brain injury in the rat. *Am J Physiol* 267:R665-R672, 1994.
186. J.P. Headrick, M.R. Bendall, A.I. FADEN and R. Vink. Dissociation of adenosine levels from bioenergetic state in experimental brain trauma: potential role in secondary injury. *J Cereb Blood Flow Metab* 14:853-861, 1994.
187. F.Y. Sun and A.I. FADEN. High and low affinity NMDA receptor-binding sites in rat spinal cord: effects of traumatic injury. *Brain Res* 664:63-69, 1994.
188. A.G. Yakovlev and A.I. FADEN. Sequential expression of c-fos protooncogene, TNF-alpha and dynorphin genes in spinal cord following experimental traumatic injury, *Molec & Chem Neuropathol*, 186:179-190, 1994.
189. A.I. FADEN and V.A. Sharpe. Iatrogenic neurological complications. *Arch Neurol* 51:1184-1185, 1994.
190. F.Y. Sun and A.I. FADEN. N-methyl-d-aspartate receptors mediate posttraumatic increases of protein kinase C in rat brain. *Brain Res* 661:63-69, 1994.
191. Yamakami, R. Vink, A.I. FADEN, T.A. Gennarelli, R. Lenkinski and T.K. McIntosh. Effects of acute ethanol intoxication on experimental brain injury in the rat: neurobehavioral and phosphorus-31 nuclear magnetic resonance spectroscopy studies. *J Neurosurg* 82:813-821, 1995.
192. J.P. Headrick, A.I. FADEN and R. Vink. Intrathecal dynorphin-A infusion in rat spinal cord causes energy depletion, edema and neurologic dysfunction. *Neurochem Int* 26(5):489-495, 1995.
193. D. Sappey-Marini, L. Chileuitt, M.W. Weiner, A.I. FADEN, and P.R. Weinstein. Hypoglycemia prevents increase in lactic acidosis during reperfusion after temporary cerebral ischemia in rats. *NMR Biomed* 8:171-178, 1995.
194. F.Y. Sun and A.I. FADEN. Neuroprotective effects of 619C89, a use-dependent sodium channel blocker, in rat. *Brain Res* 673:133-140, 1995.
195. A.Y. Yakovlev, K. Krueger and A.I. FADEN. Structure and expression of a rat kappa opioid receptor gene. *J Biological Chem* 270:6421-6424, 1995.
196. Pitts L, Ross A, Chase GA, and FADEN AI. Treatment with thyrotropin releasing hormone (TRH) in patients with traumatic spinal cord injuries. *J Neurotrauma* 12:235-243, 1995.
197. F.Y. Sun and A.I. FADEN. Pretreatment with antisense oligodeoxynucleotides directed against the NMDA-R1 receptor enhances survival and behavioral recovery following traumatic brain injury in rats. *Brain Res* 693:163-168, 1995.
198. A.G. Yakovlev and A.I. FADEN. Molecular strategies in CNS injury. *J Neurotrauma* 12(5):767-777, 1995.

199. S.P. Moore, D.M. Zapple, S.M. Smith, and A.I. FADEN. Georgetown MedNetwork: A New Software Tool for Research Administration and Oversight. *SRA Journal* 27:7-20, 1995.
200. V.A. Sharpe and A.I. FADEN. Appropriateness in patient care: a new conceptual framework. *Milbank Quarterly* 74:115-138, 1996.
201. A.I. FADEN. Pharmacological treatment of central nervous system trauma. *Pharmacology and Toxicology* 78:12-17, 1996.
202. D.M. Basso, M.S. Beattie, J.C. Bresnahan, D.K. Anderson, A.I. FADEN, J.A. Gruner, T.R. Holford, C.Y. Hsu, L.J. Noble, R. Nockels, P.L. Perot, S.K. Salzman, and W. Young. MASCIS evaluation of open field locomotor scores: effects of experience and teamwork on reliability. *J Neurotrauma* 13(7):343-359, 1996.
203. Mukhin A, Fan L, and FADEN A.I. Activation of metabotropic glutamate receptor subtype mGluR1 contributes to posttraumatic neuronal injury. *J Neurosci* 16(19):6012-6020, 1996.
204. B.A. Eldadah, A.G. Yakovlev, and A.I. FADEN. A new approach for the electrophoretic detection of apoptosis. *Nucleic Acids Res* 24(20):4092-4093, 1996.
205. A.I. FADEN. Pharmacologic treatment of acute traumatic brain injury. *JAMA* 276(7): 569-570, 1996.
206. Mukhin AG, Ivanova SA, and AI FADEN. mGluR modulation of post-traumatic neuronal death: Role of NMDA receptors. *Neuroreport* 8:2561-2566, 1997.
207. Mukhin AG, SA Ivanova, SM Knoblach, and AI FADEN. New *in vitro* model of traumatic neuronal injury: Evaluation of secondary injury and glutamate receptor mediated neurotoxicity. *J Neurotrauma* 14:651-663, 1997.
208. Eldadah BA, Yakovlev AG, and FADEN AI. The role of Ced-3-related cysteine proteases in apoptosis of cerebellar granule cells. *J Neurosci* 17(16):6105-6113, 1997.
209. Yakovlev, A.G., Knoblach, S.M., Fan, L., Fox, G.B., Goodnight, R., and FADEN, A.I. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. *J Neurosci* 17(19):7415-7424, 1997.
210. FADEN, A.I., Ivanova, S.A., Yakovlev, A.G., and Mukhin, A.G. Neuroprotective effects of group III mGluR in traumatic neuronal injury. *J Neurotrauma* 14(12):885-895, 1997.
211. Beattie MS, Bresnahan JC, Komon J, Tovar CA, Van Meter M, Anderson DK, Faden AI, Hsu CY, Noble LJ, Salzman S, Young W. Endogenous Repair after Spinal Cord Contusion Injuries in the Rat. *Exp. Neurology* 148, 453-463 (1997).
212. A.G Mukhin, S.A. Ivanova, J.W. Allen, and A.I. FADEN. Mechanical injury to neuronal/glial cultures in microplates: role of NMDA receptors and pH in secondary neuronal cell death. *J Neurosci Res*, 51:748-758, 1998.
213. G.B. Fox, L. Fan, R.A. LeVasseur and A.I. FADEN. Sustained sensory/motor and cognitive deficits associated with neuronal apoptosis following controlled cortical impact brain injury in the mouse. *J Neurotrauma*, Vol. 15: 599-614, 1998.
214. G.B. Fox and A.I. FADEN. Traumatic Brain Injury Causes Delayed Motor and Cognitive Impairment in a Mutant Mouse Strain Known to Exhibit Delayed Wallerian Degeneration. *J Neurosci Res*, 53:718-727, 1998.
215. S. Knoblach and A.I. FADEN. Interleukin-10 Improves Outcome and Alters Proinflammatory Cytokine Expression after Experimental Traumatic Brain Injury. *Exp Neurol* 153, 143-151, 1998.
216. G.B. Fox, L. Fan, R.A. LeVasseur and A.I. FADEN. Effect of traumatic brain injury on mouse spatial and non-spatial learning in the Barnes Circular Maze. *J Neurotrauma*, 15:1037-1046, 1998.
217. L Fan, AG Yakovlev, AI FADEN. Site-specific cleavage of 28S rRNA as a marker of traumatic brain injury. *J Neurotrauma* 16: 357 - 364, 1999.
218. GB Fox, RA LeVasseur, AI FADEN. Behavioral responses of C57BL/6, FVB/N and 129/SvEMS mouse strains to traumatic brain injury: implications for gene targeting approaches to neurotrauma. *J Neurotrauma* 16: 377 -389, 1999.

219. JW Allen, BA Eldadah, AI FADEN. Beta-amyloid-induced apoptosis of cerebellar granule cells and cortical neurons: exacerbation by selective inhibition of group I metabotropic glutamate receptors. *Neuropharmacology* 38:1243-1252, 1999.
220. JW Allen, SA Ivanova, L Fan, MG Espey, AS Basile, AI FADEN. Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury. *J Pharmacol Exp Ther* 290:112-120, 1999.
221. S. Knoblach, L. Fan, and A.I. FADEN. Early neuronal expression of tumor necrosis factor- $\alpha$  after experimental brain injury contributes to neurological impairment. *J Neuroimmunol* 95: 115-125, 1999.
222. JW Allen, SM Knoblach, AI FADEN. Combined mechanical trauma and metabolic impairment in vitro induces NMDA receptor-dependent neuronal cell death and caspase-3 dependent apoptosis. *FASEB J* 13 (13):1875-1882, 1999.
223. AI FADEN, GB Fox, L Fan, GL Araldi, L Qiao, Swang, AP Kozikowski. Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents. *Amer J Physiol* 27:R1196-104, 1999.
224. FADEN AI, Fox G, Fan L, Knoblach S, Araldi GL, Kozikowski AP. Neuroprotective and cognitive enhancing effects of novel small peptides. *Ann N Y Acad Sci* 890:120, 1999.
225. Albensi BC, Knoblach SM, Chew BGM, O'Reilly MP, FADEN AI, Pekar JJ. Diffusion and high resolution MRI of traumatic brain injury in rats: time course and correlation with histology. *Exp Neurol* 162(1):61-72, 2000.
226. Eldadah BA, Ren RF, FADEN AI. Ribozyme-mediated inhibition of Caspase-3 protects cerebellar granule cells from apoptosis induced by serum/potassium deprivation. *J Neurosci* 20(1):179-186, 2000.
227. Allen JW, Knoblach SM, FADEN AI. Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death *in vitro*. *Cell Death Diff* 7(5):470-476, 2000.
228. Knoblach SM, FADEN AI. Cortical interleukin-1 beta elevation after traumatic brain injury in the rat: no effect of two selective antagonists on motor recovery. *Neurosci Lett* 289(1):5-8, 2000.
229. Eldadah BA, FADEN AI. Caspase pathways, neuronal apoptosis, and CNS injury. *J Neurotrauma* 17(10):811-29, 2000.
230. Toman RE, Spiegel S, Faden AI. Role of ceramide in neuronal cell death and differentiation. *J Neurotrauma* 17(10):891-8, 2000.
231. O'Leary DM, Movsesyan V, Vicini S, FADEN AI. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. *Br J Pharmacol* 131(7):1429-37, 2000.
232. Movsesyan VA, O'Leary DM, Fan L, Bao W, Mullins PG, Knoblach SM, FADEN AI. mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors. *J Pharmacol Exp Ther* 296(1):41-7, 2001.
233. Movsesyan VA, Yakovlev AG, Fan L, FADEN AI. Effect of serine protease inhibitors on posttraumatic brain injury and neuronal apoptosis. *Exp Neurol* 167(2):366-75, 2001.
234. FADEN AI, O'Leary DM, Fan L, Bao W, Mullins PG, Movsesyan VA. Selective blockade of the mGluR1 receptor reduces traumatic neuronal injury *in vitro* and improves outcome after brain trauma. *Exp Neurol* 167(2):435-44, 2001.
235. Yakovlev AG, Di X, Movsesyan VA, Mullins PG, Wang G, Boulares H, Zhang J, Xu M, and FADEN AI. Presence of DNA fragmentation and lack of neuroprotective effect in DFF45 knockout mice subjected to traumatic brain injury. *Mol Med* 7:205-216, 2001.
236. Allen JW, Eldadah BA, Huang X, Knoblach SM, FADEN AI. Multiple caspases are involved in  $\beta$ -amyloid-induced neuronal apoptosis. *J Neurosci Res*, in press.

237. Allen JW, Vicini S, and FADEN AI. Exacerbation of neuronal cell death by activation of group I metabotropic glutamate receptors: role of NMDA receptors and arachidonic acid release. *Exp Neurol*, in press.
238. Lea P.M. IV and AI FADEN. Traumatic brain injury: developmental differences in glutamate receptor response and the impact on treatment. Special Issue: The glutamate signalling in developmental and in neonatal brain injury. *Mental Retardation & Developmental Disabilities Research Reviews*, in press.
239. FADEN AI. Neuroprotection and traumatic brain injury: the search continues. *Arch Neurol*, in press.

#### Books/Monographs

1. R. Faden and A.I. FADEN (Eds.). Ethical Issues in Public Health Policy: Health, Education and Lifestyle Interventions: Preface. *Health Educ Mono* 6: 2, 1978.
2. K.O. Stumpe, K. Kraft, and A.I. FADEN (Eds.). Opioid Peptides and Blood Pressure Control. Springer-Verlag: Berlin, Heidelberg, 1989.
3. P. Weinstein and A.I. FADEN (Eds.). Protection of the Brain from Ischemia. Williams and Wilkins, 1990.
4. S. Salzman and A.I. FADEN (Eds.), Neurobiology of CNS Trauma, Oxford University Press: New York, 1994.
5. A.I. FADEN (Ed.). *J Neurotrauma*, Special Edition on Molecular Neurobiology, 12(5), 1995.
6. V.A. Sharpe and A.I. FADEN. Medical Harm: Historical, Conceptual and Ethical Dimensions of Iatrogenic Illness. Cambridge University Press: Cambridge, UK, 1998.
7. E. Pellegrino and A.I. FADEN (Eds), Biomedical Ethics: A Jewish-Catholic Dialogue, Georgetown University Press: Washington, D.C., 1999.
8. AI FADEN (ed). *J Neurotrauma*, Special Issue on Apoptosis in Central Nervous System Injury plus Abstracts from the Eighteenth Annual National Neurotrauma Society Symposium, 17(10), 2000.

#### Book Chapters

1. J.W. Holaday, G.L. Belenky, A.I. FADEN, and H.H. Loh. Possible function of b-endorphin. *In: Saletu, B. (Ed.), Neuropsychopharmacology*. Pergamon Press: London, pp. 503-514, 1979.
2. A.I. FADEN and J.W. Holaday. Naloxone reversal of hypotension caused by spinal transection. *In: Way, E.L. (Ed.), Endogenous and Exogenous Opiate Agonists and Antagonists*. Pergamon Press: London, pp. 483-486, 1980.
3. J.W. Holaday and A.I. FADEN. Naloxone improvement of shock pathophysiology: Evidence for opiate receptor involvement. *In: Way E.L. (Ed.), Endogenous and Exogenous Opiate Agonists and Antagonists*. Pergamon Press: London, pp. 479-482, 1980.
4. J.W. Holaday and A.I. FADEN. Endorphin involvement in the pathophysiology of shock and trauma: Therapeutic effects of Naloxone. *In: Biro, Z.S., Kovach, A.G.B., Spiker, J.J., Stoner, H.B. (Eds.), Homeostasis and Injury in Shock*, Akademiai Kiado. Pergamon Press: Budapest, pp. 131-141, 1981.
5. J.W. Holaday and A.I. FADEN. Naloxone and thyrotropin-releasing hormone have additive effects in reversing endotoxic shock. *In: Takai, H. et al. (Eds.), Advances in Endogenous and Exogenous Opioids*. Pergamon Press: Oxford, pp. 367-370, 1981.
6. J.W. Holaday and A.I. FADEN. Endorphins and thyrotropin releasing hormone in shock and trauma. *In: Yoshida, M. et al. (Eds.), Advances in Pharmacology and Therapeutics*. Pergamon Press: Oxford, pp. 45-55, 1982.



7. A.I. FADEN. Neuropeptides in shock and neural injury. *In: Chernow, B., Lake, C.R. (Eds.), The Pharmacologic Approach to the Critically Ill Patient. Williams and Wilkins: Baltimore, pp. 636-649, 1983.*
8. J.W. Holaday and A.I. FADEN. Thyrotropin-releasing hormone reverses experimental circulatory shock: Central and peripheral actions of TRH and analogs. *In: Griffiths, E.C., Bennett, G.W. (Eds.), Thyrotropin-Releasing Hormone. Raven Press: Baltimore, pp. 372-373, 1983.*
9. A.I. FADEN. Pharmacologic therapy in acute spinal cord injury: Experimental strategies and future directions. *In: Becker, D.P., Povlishock, J.T. (Eds.), Central Nervous System Trauma Status Report (1985). NINCDS: Bethesda, MD, pp. 481-485, 1985.*
10. T.K. McIntosh, S. Fernyak, and A.I. FADEN. Endogenous opioids, opiate receptors and traumatic brain injury. *In: Progress in Opioid Research. NIDA Research Monograph Series, pp. 527-530, 1986.*
11. A.I. FADEN and T.K. McIntosh. Endogenous opioids and central cardiovascular control. *In: Strober, T. et al. (Eds.), CNS Control of the Heart. Martinus Nijhoff Publishing: New York, pp. 123-134, 1987.*
12. A.I. FADEN. New pharmacologic approaches to the therapy of acute spinal cord injury. *In: Ghista, D.J. (Ed.), Spinal Cord Injury Medical Engineering. 1987.*
13. A.I. FADEN. The role of endogenous opioids and opiate receptors in the pathogenesis of CNS injury. *In: Sances, A., Jr. (Ed.), Mechanisms of Head and Spine Trauma. Martinus Nijhoff Publishing: New York, 1987.*
14. T.K. McIntosh and A.I. FADEN. Opiate antagonists in CNS injury. *In: Pharmacologic Approaches to Recovery from Brain Injuries. Plenum Press, 1987.*
15. P. Demediuk and A.I. FADEN. Arachidonic acid metabolites and membrane lipid changes in central nervous system injury. *In: Stein, D., Sabel, B. (Eds.), Pharmacologic Approaches to the Treatment of Brain and Spinal Cord Injury. Plenum Press, pp. 23-42, 1987.*
16. A.I. FADEN. Role of TRH and opiate receptor antagonists in limiting central nervous system injury. *In: Waxman, S. (Ed.), Physiological Basis for Functional Recovery in Neurological Disease. Raven Press: New York, 47: 531-546, 1988.*
17. A.I. FADEN, R. Vink, and T.K. McIntosh. Thyrotropin-releasing hormone and central nervous system trauma. *In: Metcalf, G., Jackson, I.M.D. (Eds.), Thyrotropin Releasing Hormone: Biomedical Significance. Ann NY Acad Sci, 553: 380-384, 1989.*
18. A.I. FADEN. Effects of TRH on blood flow, circulatory shock, and CNS injury: Summary of section VIII. *In: Metcalf, G., Jackson, I.M.D. (Eds.), Thyrotropin Releasing Hormone: Biomedical Significance. Ann NY Acad Sci, 553: 385-387, 1989.*
19. A.I. FADEN and R. Vink. Chemical pathobiology of CNS trauma. *In: Bihari, D., Holaday, J.W. (Eds.), Update in Intensive Care and Emergency Medicine. Springer-Verlag: Berlin, 9: 14-21, 1989.*
20. R. Vink, T.K. McIntosh, and A.I. FADEN. Magnetic resonance spectroscopy and the *in vivo* characterization of cerebral metabolism following brain injury. *In: Yearbook of the Encyclopedia of Neuroscience: Neuroscience Year. Birkhauser: Cambridge, MA., pp. 51-53, 1989.*
21. R. Vink, T.K. McIntosh, and A.I. FADEN. Magnesium in CNS trauma. *In: Yearbook of the Encyclopedia of Neuroscience: Neuroscience Year. Birkhauser: Cambridge, MA., pp. 149-151, 1989.*
22. A.I. FADEN. Opioids, opiate receptors, and central cardiovascular regulation. *In: Opioid Peptides and Blood Pressure Control. Springer-Verlag: Berlin, pp. 53-61, 1989.*
23. A.I. FADEN. Role of opiate antagonists in the treatment of stroke. *In: Weinstein, P., FADEN, A.I. (Eds.), Protection of the Brain from Ischemia. Williams and Wilkins: Baltimore, pp. 265-271, 1990.*
24. R. Vink, T.K. McIntosh, and A.I. FADEN. Magnesium in neurotrauma: Its role, and therapeutic implications. *In: Scarpa, P., Carbone, E. (Eds.), Magnesium and Excitable Membranes. Springer-Verlag: Berlin, pp. 125-145, 1991.* W.K. Doyle, C. Wilmot, K.M. Hall, P.R. Cooper, and A.I. FADEN. Trauma of the spine and spinal cord. *In: Joynt, R. (Ed.), Clinical Neurology. J. B. Lippincott Co., Vol. 3, Ch. 47, pp. 1-58, 1991.*

25. A.I. FADEN, P. Weinstein, R. Bakshi, S. Yum, M. Lemke, and S. Graham. Biochemical changes and secondary tissue injury after brain and spinal cord ischemia. *In: Bazan, N.G., BRAQUET, P., Ginsberg, M.D.(Eds.), Neurochemical Correlates of Cerebral Ischemia*. S. Karger AG, Basel, Ch. 9, pp. 161-181, 1992.
26. S.S. Panter and A.I. FADEN. Biochemical changes and secondary injury from stroke and trauma. Chapter 4. *In: Young, R.R., Delwade, P.J. (Eds.), Principles and Practice of Restorative Neurology*. Butterworths: New York, pp. 32-52, 1992.
27. A.I. FADEN. Role of opioids in central cardiovascular regulation and dysregulation. *In: Herz, A., Akil, H., and Simon, E.J. (Eds.), Chapter 37. Handbook of Experimental Pharmacology*. Springer-Verlag: Berlin, pp. 191-204, 1993.
28. A.I. FADEN. Role of opioids in central nervous system injury. *In: Herz, A., Akil, H., and Simon, E.J. (Eds.), Chapter 43: Handbook of Experimental Pharmacology*. Springer-Verlag: Berlin, pp. 325-341, 1993.
29. A.I. FADEN and S. Salzman. Experimental pharmacology. *In: Neurobiology of CNS Trauma*. Oxford University Press: New York, pp. 227-245, 1994.
30. A.I. FADEN and S. Salzman. Neurotraumatology: Future directions. *In: Neurobiology of CNS Trauma*. Oxford University Press: New York, 1994.
31. T.K. McIntosh and A.I. FADEN. Endogenous opioid peptides and traumatic central nervous system injury. *In: Neurobiology of CNS Trauma*. Oxford University Press: New York, 1994.
32. A.I. FADEN. Pharmacotherapeutic treatment approaches for brain and spinal cord trauma. *In: Neurotrauma*. (R. Narayan, J. Wilberger, and J. Povlishock, eds.). McGraw-Hill: New York, 11:1479-1490, 1996.
33. A.I. FADEN. Therapeutic approaches to spinal cord injury. *In: Seil, F.J. (Ed.), Lippincott-Raven Publishers: Philadelphia, Vol. 72; Ch. 35, pp. 377-386, 1997.*
34. R. Vink, T.K. McIntosh and A.I. FADEN. Brain injury: metabolic aspects using magnetic resonance. *In: Encyclopedia of Neuroscience on CD ROM*, 2nd ed.(G. Adelman and B. Smith, eds.). Elsevier: New York, 1997.
35. A. Yakovlev and A.I. FADEN. Traumatic brain injury regulates expression of Ced-related genes modulating neuronal apoptosis. *In: Neurotraumatology: Biomechanic Aspects, Cytologic and Molecular Mechanisms*. Schmidt-Römhild, Lübeck, pp. 107-120, 1997.
36. A.I. FADEN. Iatrogenic illness: an overview with particular reference to neurologic complications. *In: Neurologic Clinics*. W.B. Saunders Company: Philadelphia, Vol. 16(1), pp. 1-8, 1998.
37. Temple M, O'Leary D, and FADEN A. The role of glutamate receptors in the pathophysiology of traumatic brain injury. *In: Head Trauma*, L. Miller, R. Hayes, and J. Newcomb, Eds. New York: John Wiley & Sons, 2001; pp. 87-113.

### Proceedings

1. J.W. Holaday and A.I. FADEN. The role of endorphins in the pathophysiology of shock and the therapeutic benefit of opiate antagonists. *Army Sci Conf Proc* 2: 233-246, 1980.
2. E.A. Zimmerman, R.L. MacDonald, W. Vale, and A.I. FADEN. Symposium on neuropeptides. *Trans Am Neurol Assoc* 105: 504-527, 1980.
3. A.I. FADEN and J.W. Holaday. A role for endorphins in the pathophysiology of spinal cord injury. *Adv Biochem Psychopharmacol* 28: 435-446, 1981.
4. A.I. FADEN and J.W. Holaday. Endorphins in traumatic spinal injury: Pathophysiologic studies and clinical implications. *Mod Probl Pharmacopsych* 17: 158-174, 1981.
5. J.W. Holaday and A.I. FADEN. Endorphins in shock and spinal injury: Therapeutic role for opiate antagonists. *Psychopharmacol Bull* 17: 74-76, 1981.
6. J.W. Holaday and A.I. FADEN. Naloxone reverses the pathophysiology of shock through an antagonism of endorphin systems. *Adv Biochem Psychopharmacol* 28: 421-434, 1981.
7. A.I. FADEN, T.P. Jacobs, and J.W. Holaday. Neuropeptides and spinal cord injury. *Adv Biochem Psychopharmacol* 33: 131-138, 1982.

8. J.W. Holaday, R. D'Amato, B.A. Ruvio, and A.I. FADEN. Action of Naloxone and TRH on the autonomic regulation of the circulation. *Adv Biochem Psychopharmacol* 33: 353-361, 1982.
9. W.E. Lux, Jr., G. Feuerstein, G.P. Smith, and A.I. FADEN. Effects of pharmacological interventions on leukotriene D<sub>4</sub> hypotension in the unanesthetized guinea pig. *In: Piper PJ (Ed.), Advances in Prostaglandins, Thromboxane and Leukotriene Research*, Chichester, England: John Wiley & Sons, pp. 338-342, 1982.
10. Z. Zukowska-Grojec, M. Bayorh, A.I. FADEN, and G. Feuerstein. Pharmacological interventions in the cardiac and vascular effects of leukotriene D<sub>4</sub> in spontaneously hypertensive rats. *In: Piper, P.J. (Ed.), Advances in Prostaglandins, Thromboxane and Leukotriene Research*, Chichester, England: John Wiley & Sons, pp. 113-120, 1983.
11. J.W. Holaday and A.I. FADEN. Spinal shock and injury: Experimental therapeutic approaches. *Adv. Shock Res.* 10: 95-98, 1983.
12. A.I. FADEN and T.P. Jacobs. Experimental spinal cord injury: Treatment with Naloxone and TRH. *In: Dacey, R.G. et al. (Eds.), Proceedings of the Fifth Neurotrauma Conference*. Raven Press: New York, pp. 259-265, 1985.
13. T.K. McIntosh, R. Vink, and A.I. FADEN. Beneficial effect of the TRH analog CG-3703 on outcome and survival following traumatic brain injury in rats. *In: Bond R (Ed.), First International Shock Congress*. Alan R. Liss: New York, pp. 415-420, 1988.
14. P. Demediuk, M. Lemke, and A.I. FADEN. Spinal cord edema and changes in tissue content of Na<sup>+</sup>, K<sup>+</sup>, and Mg<sup>2+</sup> following impact trauma in rats. *Proceedings of the International Brain Edema Meetings*. Raven Press: New York, 52: 225-231, 1990.
15. A.I. FADEN. Neurotoxic versus neuroprotective actions of endogenous opioid peptides: implications for treatment of CNS injury. *In: NIDA Research Monograph, NIDA Conference* 163:318-330, 1996.